Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Muscle & Nerve|March 5, 2013
Anterior tibialis CMAP amplitude correlations with impairment in CMT1AKelsey Komyathy, Stephanie Neal, Shawna Feely, et al.Stem Cell Research|April 14, 2018
Generation of Duchenne muscular dystrophy patient-specific induced pluripotent stem cell line lacking exons 45-50 of the dystrophin gene (IITi001-A)Binyamin Eisen, Ronen Ben Jehuda, Ashley J Cuttitta, et al.CPT: Pharmacometrics & Systems Pharmacology|September 17, 2025
Nipocalimab Dose Selection in Generalized Myasthenia GravisBelén Valenzuela, Martine Neyens, Yaowei Zhu, et al.Annals of Neurology|November 22, 2020
Development and Validation of the Pediatric Charcot-Marie-Tooth Disease Quality of Life Outcome MeasureSindhu Ramchandren, Tong Tong Wu, Richard S Finkel, et al.Journal of the Peripheral Nervous System : JPNS|April 13, 2022
Validation of the Italian version of the pediatric CMT quality of life outcome measureIsabella Moroni, Federica Rachele Danti, Davide Pareyson, et al.Journal of the Peripheral Nervous System : JPNS|February 7, 2023
Validation of the parent-proxy pediatric Charcot-Marie-Tooth disease quality of life outcome measureTong Tong Wu, Richard S Finkel, Carly E Siskind, et al.Journal of the Peripheral Nervous System : JPNS|February 8, 2024
Parent-proxy pediatric CMT quality of life outcome measure: Validation of the Italian versionFederica Rachele Danti, Emanuela Pagliano, Davide Pareyson, et al.Journal of the Peripheral Nervous System : JPNS|May 11, 2023
Validation of the parent-proxy version of the pediatric Charcot-Marie-Tooth disease quality of life instrument for children aged 0-7 yearsTong Tong Wu, Richard S Finkel, Carly E Siskind, et al.Advances in Therapy|March 12, 2026
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia GravisSaiju Jacob, Mahmoud Hashim, Brian Hutton, et al.European Journal of Neurology|May 20, 2026
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 StudyTuan Vu, Said R Beydoun, Richard J Nowak, et al.Pageof 5